270 related articles for article (PubMed ID: 22211893)
1. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Gallagher EJ; LeRoith D
Ann N Y Acad Sci; 2011 Dec; 1243():54-68. PubMed ID: 22211893
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus and the risk of cancer.
Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
[TBL] [Abstract][Full Text] [Related]
3. [Diabetes and cancer risk: oncologic considerations].
Rosta A
Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
[TBL] [Abstract][Full Text] [Related]
4. Metformin and cancer: licence to heal?
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Investig Drugs; 2010 Aug; 19(8):913-7. PubMed ID: 20557275
[TBL] [Abstract][Full Text] [Related]
5. [Correlations of insulin resistance and neoplasms].
Suba Z; Ujpál M
Magy Onkol; 2006; 50(2):127-35. PubMed ID: 16888676
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and cancer: a consensus report.
Giovannucci E; Harlan DM; Archer MC; Bergenstal RM; Gapstur SM; Habel LA; Pollak M; Regensteiner JG; Yee D
CA Cancer J Clin; 2010; 60(4):207-21. PubMed ID: 20554718
[TBL] [Abstract][Full Text] [Related]
7. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
Algire C; Amrein L; Bazile M; David S; Zakikhani M; Pollak M
Oncogene; 2011 Mar; 30(10):1174-82. PubMed ID: 21102522
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and cancer.
Chowdhury TA
QJM; 2010 Dec; 103(12):905-15. PubMed ID: 20739356
[TBL] [Abstract][Full Text] [Related]
9. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.
Algire C; Zakikhani M; Blouin MJ; Shuai JH; Pollak M
Endocr Relat Cancer; 2008 Sep; 15(3):833-9. PubMed ID: 18469156
[TBL] [Abstract][Full Text] [Related]
10. A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose.
García-Jiménez C; García-Martínez JM; Chocarro-Calvo A; De la Vieja A
J Mol Endocrinol; 2014 Feb; 52(1):R51-66. PubMed ID: 24049067
[TBL] [Abstract][Full Text] [Related]
11. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
12. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes.
Wiernsperger NF
Diabetes Metab; 1999 Jun; 25(2):110-27. PubMed ID: 10443322
[TBL] [Abstract][Full Text] [Related]
13. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
Gupta A; Bisht B; Dey CS
Neuropharmacology; 2011 May; 60(6):910-20. PubMed ID: 21277873
[TBL] [Abstract][Full Text] [Related]
14. Metformin as an antitumor agent in cancer prevention and treatment.
Li D
J Diabetes; 2011 Dec; 3(4):320-7. PubMed ID: 21631893
[TBL] [Abstract][Full Text] [Related]
15. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.
Pierotti MA; Berrino F; Gariboldi M; Melani C; Mogavero A; Negri T; Pasanisi P; Pilotti S
Oncogene; 2013 Mar; 32(12):1475-87. PubMed ID: 22665053
[TBL] [Abstract][Full Text] [Related]
17. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Goodwin PJ; Stambolic V
Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
[TBL] [Abstract][Full Text] [Related]
18. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia.
Smith AC; Mullen KL; Junkin KA; Nickerson J; Chabowski A; Bonen A; Dyck DJ
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E172-81. PubMed ID: 17374701
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Phillips JW; Barringhaus KG; Sanders JM; Yang Z; Chen M; Hesselbacher S; Czarnik AC; Ley K; Nadler J; Sarembock IJ
Circulation; 2003 Oct; 108(16):1994-9. PubMed ID: 14517165
[TBL] [Abstract][Full Text] [Related]
20. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
